Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3- mutated acute myeloid leukemia patients - Czech center experience

Barbora Weinbergerová; Martin Čerňan; Tomáš Kabut; Lukáš Semerád; Natália Podstavková; Tomáš Szotkowski; Ivana Ježíšková; Jiří Mayer

doi:10.3324/haematol.2022.282263

Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3- mutated acute myeloid leukemia patients - Czech center experience

Haematologica. 2023 Oct 1;108(10):2826-2829. doi: 10.3324/haematol.2022.282263.

Authors

Barbora Weinbergerová¹, Martin Čerňan², Tomáš Kabut³, Lukáš Semerád³, Natália Podstavková³, Tomáš Szotkowski², Ivana Ježíšková³, Jiří Mayer³

Affiliations

¹ Department of Internal Medicine - Hematology and Oncology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. [email protected].
² Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
³ Department of Internal Medicine - Hematology and Oncology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.

No abstract available

Publication types

Letter

MeSH terms

Czech Republic
Gemtuzumab
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Staurosporine / therapeutic use
fms-Like Tyrosine Kinase 3 / genetics

Substances

Gemtuzumab
midostaurin
Staurosporine
FLT3 protein, human
fms-Like Tyrosine Kinase 3

Grants and funding

Funding: This study was supported by the Czech Republic Ministry of Health-conceptual development of research organization (FNBr, 65269705) and the National Institute for Cancer Research Project (Programme EXCELES, ID Project N. LX22NPO5102) funded by the European Union-Next Generation EU.